Treatment of retinal pigment epithelial detachment with antiangiogenic therapy
Luis AriasDepartment of Ophthalmology, Bellvitge University Hospital, Barcelona, SpainPurpose: Evaluate the efficacy of pegaptanib, a selective anti-vascular endothelial growth factor (VEGF) agent, and bevacizumab, a nonselective anti-VEGF agent, for retinal pigment epithelial detachment (PED) assoc...
Enregistré dans:
Auteur principal: | Luis Arias |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2010
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/c598f1e30e1748de9e5ed090f0b94d17 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Efficacy of reduced-fluence photodynamic therapy for serous retinal pigment epithelial detachment with choroidal hyperpermeability
par: Shibata A, et autres
Publié: (2013) -
Optimizing visualization in enhanced depth imaging OCT in healthy subjects and patients with retinal pigment epithelial detachment
par: Kampik A, et autres
Publié: (2012) -
Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab
par: Yamashita M, et autres
Publié: (2014) -
Bimonthly half-dose ranibizumab in large pigment epithelial detachment and retinal angiomatous proliferation with high risk of retinal pigment epithelium tear: a case report
par: Monés J, et autres
Publié: (2013) -
Half-dose photodynamic therapy for serous non-neovascular retinal pigment epithelial detachment
par: Inoda S, et autres
Publié: (2019)